Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Abstract PO5-06-10: Evaluating Disparities in Access to Quality Cancer Care for Black Women with Triple Negative Breast Cancer in the US: A Provider Perspective
Effange, Doreen, Dixit, Niharika , O’Regan, Ruth, Kalu, Ogori, Norcereto, Ryann, Simonds, R. J., Valencia, Elizabeth , Bolds-Johnson, LaToya , Mangir, C., Tacka, Karen, Simonds, Richard, Villalobos, Aubrey Van Kirk , Plotkin, Elana , Boehmer, Leigh

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: PO5-06-10-PO5-06-10

10.1158/1538-7445.sabcs23-po5-06-10 Get It

Abstract Introduction: Triple-negative breast cancer (TNBC) presents unique challenges due to its aggressive nature and limited treatment options. Black women are disproportionately affected by TNBC, experiencing higher incidence rates and poorer outcomes compared to other racial/ethnic groups. This study aims to evaluate disparities in access to quality cancer care for Black women with TNBC from the perspective of oncology healthcare providers. Methods: From December 2022 to February 2023, the Association of Community Cancer Centers conducted a survey of 84 multidisciplinary care team members who provided care to Black patients with TNBC. The online survey captured quantitative and qualitative data on challenges related to accessing timely TNBC diagnosis and treatment services, care coordination for work-up and biomarker testing, confidence in TNBC treatment, clinical trial enrollment, supportive care services, and related referrals. Additionally, a follow-up focus group was conducted in May 2023 to further interpret select survey data, with a focus on shared decision-making, patient-provider communication, and ways to support cancer programs in improving screening, biomarker testing, and care coordination for individuals with TNBC. Results: Respondents reported several barriers to accessing timely diagnosis and treatment services for Black women with TNBC, including challenges in coordinating care for work-up and biomarker testing, providers' confidence in providing guideline-concordant comprehensive cancer care services for this patient population, enrolling patients in clinical trials, and making referrals for supportive care services. The survey revealed that community cancer programs treated an average of 21-50 patients with TNBC annually, with 31% of them being Black. Perceived patient-level factors contributing to challenges in accessing TNBC diagnosis and treatment included geographic distance to care facilities (14%), health literacy (18%), and insurance-related factors (21%). Practice-level barriers included limited accessibility of practice location (19%), capacity to accommodate new patients (27%), and insurance-related factors (34%). Additional findings highlighted slightly lower provider confidence in areas such as tobacco cessation (only 54% very confident), breast reconstruction (59% very confident), fertility counseling (52% very confident), and coordinating care across a fragmented healthcare system (52% very confident). Respondents identified the most commonly offered comprehensive cancer care services as palliative care (82%), nutrition support (77%), telemedicine (68%), psychological counseling (68%), and financial advocacy (68%). Less commonly offered services include recreational therapy (21%), legal aid (17%), and childcare (16%). Conclusion: This study highlighted the barriers faced by providers in delivering quality cancer care to Black women with TNBC. The findings underscore the importance of addressing challenges related to timely diagnosis and treatment services, care coordination, confidence in treatment options, clinical trial enrollment, and referrals for supportive care services. Insights from the focus group discussions further highlight the need for shared decision-making, improved patient-provider communication, and identification of opportunities to support cancer programs in addressing the specific needs of Black women with TNBC. To advance equity in cancer care, targeted interventions should focus on enhancing provider education, improving care coordination systems, and promoting cultural sensitivity. Efforts should also be made to overcome barriers related to limited accessibility of practice location, and insurance-related factors. By addressing these gaps, providers can play a crucial role in reducing disparities and improving outcomes for Black women with TNBC. Citation Format: Doreen Effange, Niharika Dixit, Ruth O'Regan, Ogori Kalu, Ryann Norcereto, Richard Simonds, Elizabeth Valencia, LaToya Bolds-Johnson, Aubrey Van Kirk Villalobos, Christie Mangir, Elana Plotkin, Karen Tacka, Leigh Boehmer. Evaluating Disparities in Access to Quality Cancer Care for Black Women with Triple Negative Breast Cancer in the US: A Provider Perspective [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO5-06-10.
Heart Transplantation for Ebstein Anomaly due to Late Surgical Presentation
Leng, Tomas , Dearani, Joseph A. , Stephens, Elizabeth H. , Johnson, Jonathan N. , Dearani, Joseph A.

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | May 2, 2024 | Volume: 15 | Issue: 5 | Pages: 658-660

10.1177/21501351241239305 | PMID 38693812 Get It

Ebstein anomaly is a myopathy of the right ventricle characterized by failure of tricuspid valve delamination with accompanying tricuspid regurgitation. Its rarity, considerable anatomic variability, and frequent absence of symptoms can make the timing of surgery challenging. Contemporary tricuspid repair techniques can be performed with low mortality and bidirectional cavopulmonary anastomosis reduces the risk of operation when right ventricular function is poor. Here, we present a patient who presented late for surgery, failed high-risk conventional surgery and required heart transplantation.
US Bronchiectasis and NTM Research Registry: Pseudomonas Treatment Patterns in Non-cystic Fibrosis Bronchiectasis Measured by Sociodemographic Factors
Felzer, Jamie , Chalmers, Sarah , McShane, Pamela J. , Johnson, Margaret M. , Winthrop, Kevin , Jakharia, K., Lapinel, N. , Richards, C. , Aksamit, T.R., Brunton, Amanda E. , Choate, Radmila , Maselli, Diego J , Zha, Beth Shoshanna , Restrepo, Marcos I , Metersky, Mark L.

Mayo Clinic

B26. UNLOCKING NTM/BRONCHIECTASIS MYSTERIES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A3163-A3163

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3163 Get It

Single Breath Diffusing Capacity of the Lungs for Carbon Monoxide and Nitric Oxide in Patients With Persistent Symptoms After COVID Infection
Parks, Jen, Shea, M., McCoy, R. P., Donkor, Joshua, Kim, Changeun , Ziegler, Briana, Johnson, Bruce D., Parks, J., Wheatley, C.M., Shea, M., McCoy, R., Carlson, A., Johnston, J.

Mayo Clinic

C75. STRUCTURAL AND FUNCTIONAL CONSEQUENCES OF COVID | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6470-A6470

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6470 Get It

Discordance Simulation Testing of a Novel Phrenic Nerve Neurostimulation Device
Bentley, I., Johnson, Bruce D., Jocewicz, F.T., Mehta, Hrishikesh , Jocewicz, Frank T., Mehta, H.

Mayo Clinic

A67. COUGH, VENTILATORY CONSTRAINTS, AND NEURAL VENTILATORY CONTROL: IMPLICATIONS TO PULMONARY REHABILITATION | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2452-A2452

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2452 Get It

Inspiratory and Expiratory Lag Times for a Novel Phrenic Nerve Stimulation Device
Bentley, Ishmael, Jocewicz, Frank T., Johnson, Bruce D., Mehta, Hetal H., Mehta, H.

Mayo Clinic

A67. COUGH, VENTILATORY CONSTRAINTS, AND NEURAL VENTILATORY CONTROL: IMPLICATIONS TO PULMONARY REHABILITATION | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2451-A2451

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2451 Get It

Exhaustive Exercise Alters Exhaled Breath Volatile Organic Compounds: Insights From Elite Ultra-marathon Runners
Chou, Hong , Arthur, Keith, Shaw, Edward , Schaber, Chad , Boyle, B., Allsworth, Max, Kelley, E.F., Schwartz, Jesse C., Ziegler, Briana, Johnson, Kenneth A. , Robach, Paul , Basset, P., Johnson, Bruce D., Chou, H., Arthur, K., Shaw, E., Davies, H., Stewart, Glenn M. , Wheatley, C.M., Fermoyle, Caitlin C. , Johnson, K.

Mayo Clinic

A71. CUTTING EDGE TECHNOLOGIES FOR LUNG DISCOVERY | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2557-A2557

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2557 Get It

Aerosol Generation Using Different Delivery Methods During Simulated Bronchodilator Challenge Testing in the Pulmonary Function Laboratory
Gmehlin, C.G., Sajgalik, Pavol , Hainy, M., Chul-Ho, K., Johnson, Bruce D. , Allison, Thomas G. , Chul-Ho, K., Lim, Kaiser G. , Niven, Alexander S.

Mayo Clinic

A75. REVISITING CURRENT METHODS IN PULMONARY FUNCTION TESTING | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2626-A2626

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2626 Get It

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
Wagemann, Olivia , Shi, Xinyu , Bittner, Tobias , Scelsi, Marzia A. , Farlow, Martin R. , Clifford, David B. , Santacruz, Anna , Aschenbrenner, Andrew J. , Hassenstab, Jason , Gordon, Brian A. , Coalier, Kelley A., Perrin, Richard J., Xiong, Chengjie , Li, Yan , Morris, John C. , Lah, James J., Berman, Sarah , Roberson, Erik D. , Dyck, Christopher H. van, Gauthier, Serge , Pariente, Jérémie , Mummery, Catherine J. , Day, Gregory S. , Ringman, John M. , Méndez, Patricio Chrem, Fox, Nick C. , Okhravi, Hamid , Chhatwal, Jasmeer P. , Xiong, Chengjie , Sims, John R. , Holdridge, Karen C. , Proctor, Nicholas K. , Yaari, R. , Andersen, Scott W. , Mancini, Michele , Unit, Dominantly Inherited Alzheimer Network–Trials, Daniels, Alisha , Courtney, Laura, Lu, Ruijin , Gremminger, Emily, Franklin, Erin , Jerome, Gina, Herries, Elizabeth, Baker, Bryce, Minton, Matthew, Goate, Alison , Picarello, Danielle M. , Hornbeck, Russ C. , Chen, Allison , Chen, Charles D., Jarman, Steve, Jackson, Kelley, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Sabaredzovic, Edita, Smith, Hunter , Scott, Jalen , Simmons, Ashlee, Rizzo, Jacqueline, Barthélemy, Nicolas R. , Xu, Jinbin , Ikonomović, Snežana, Nadkarni, Neelesh K. , Graff‐Radford, Neill R. , Huey, Edward D. , Salloway, Stephen , Bechara, Jacob , Ryan, Natalie S. , Laske, Christoph , Hofmann, Anna, Kuder-Buletta, Elke, Gräber‐Sultan, Susanne, Obermueller, Ulrike, Roedenbeck, Yvonne, Sánchez‐Valle, Raquel , Vázquez, Silvia , Leon, Yudy Milena, Ramírez, Laura, Seyfried, Nicholas T. , Fagan, Anne M. , Mori, Hiroshi , Gordon, Brian A , Roberson, Erik , Sánchez-Valle, Raquel , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Goate, Alison M , Berman, Sarah , Liu, Haiyan , Wang, Guoqiao , Supnet, Charlene , Benzinger, Tammie L.S. , Cruchaga, Carlos , Ibanez, Laura , Li, Yan, Dyck, Christopher H. van , Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Brooks, William S. , George‐Hyslop, Peter St , Suzuki, Kazushi , Jucker, Mathias , Mancini, Michele, Llibre‐Guerra, Jorge J. , Bateman, Randall J. , McDade, Eric , Unit, Dominantly Inherited Alzheimer Network–Trials, Xu, Xiong, Stauber, Jennifer, Renton, Alan , Flores, Shaney , Joseph‐Mathurin, Nelly , McCullough, Austin , McKay, Nicole S. , Wáng, Qīng , Smith, Jennifer A. , Stout, Sarah Holtz , Karch, Celeste M. , Marsh, Jacob A. , Holtzman, David M. , Noble, James M. , Ikeuchi, Takeshi , Kasuga, Kensaku , Niimi, Yoshiki , Schofield, Peter R. , Martins, Ralph N. , Cash, David M. , Vöglein, Jonathan , Lee, Jae‐Hong , Roh, Jee Hoon , Rosa-Neto, Pedro , Allegri, Ricardo , Surace, Ezequiel , Lopera, Francisco Javier , Aguillon, David , Levey, Allan I. , Johnson, Erik C. B. , Masters, Colin L.

Mayo Clinic

JAMA Neurology | April 29, 2024 | Volume: 81 | Issue: 6 | Pages: 582

10.1001/jamaneurol.2024.0991 | PMID 38683602 Get It

Importance Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD). Objective To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment. Design, Setting, and Participants From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conducted from April to June 2023. DIAN-TU-001 spans 25 study sites in 7 countries. Biofluids and neuroimaging from carriers of DIAD gene variants in the gantenerumab, solanezumab, and placebo groups were analyzed. Interventions In 2016, initial dosing of gantenerumab, 225 mg (subcutaneously every 4 weeks) was increased every 8 weeks up to 1200 mg. In 2017, initial dosing of solanezumab, 400 mg (intravenously every 4 weeks) was increased up to 1600 mg every 4 weeks. Main Outcomes and Measures Longitudinal changes in CSF levels of neurogranin, soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase 3–like 1 protein (YKL-40), glial fibrillary acidic protein (GFAP), neurofilament light protein (NfL), and plasma levels of GFAP and NfL. Results Of 236 eligible participants screened, 43 were excluded. A total of 142 participants (mean [SD] age, 44 [10] years; 72 female [51%]) were included in the study (gantenerumab, 52 [37%]; solanezumab, 50 [35%]; placebo, 40 [28%]). Relative to placebo, gantenerumab significantly reduced CSF neurogranin level at year 4 (mean [SD] β = −242.43 [48.04] pg/mL; P < .001); reduced plasma GFAP level at year 1 (mean [SD] β = −0.02 [0.01] ng/mL; P = .02), year 2 (mean [SD] β = −0.03 [0.01] ng/mL; P = .002), and year 4 (mean [SD] β = −0.06 [0.02] ng/mL; P < .001); and increased CSF sTREM2 level at year 2 (mean [SD] β = 1.12 [0.43] ng/mL; P = .01) and year 4 (mean [SD] β = 1.06 [0.52] ng/mL; P = .04). Solanezumab significantly increased CSF NfL (log) at year 4 (mean [SD] β = 0.14 [0.06]; P = .02). Correlation analysis for rates of change found stronger correlations between CSF markers and fluid markers with Pittsburgh compound B positron emission tomography for solanezumab and placebo. Conclusions and Relevance This randomized clinical trial supports the importance of fibrillar amyloid reduction in multiple AD-related processes of neuroinflammation and neurodegeneration in CSF and plasma in DIAD. Additional studies of antiaggregated amyloid therapies in sporadic AD and DIAD are needed to determine the utility of nonamyloid biomarkers in determining disease modification. Trial Registration ClinicalTrials.gov Identifier: NCT04623242